|Day Low/High||30.35 / 31.40|
|52 Wk Low/High||14.70 / 50.11|
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 364,111 share decrease in total short interest for Five Prime Therapeutics, Inc , to 2,536,773, a decrease of 12.55% since 02/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Investors in Five Prime Therapeutics, Inc saw new options become available this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FPRX options chain for the new May 19th contracts and identified one put and one call contract of particular interest.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMG, BABA, BOKF, BWEN, CQP, NCOM, PCTY, PFLT, SHEN, TLF Downgrades: DIN, FPRX, GNC, WILC Initiations: CLIR, OMNT Read on to get TheStreet Quant Ratings' detailed report:
Cabiralizumab (FPA008) is in a Phase 2 clinical trial for rare neoplastic joint disease for which there are no currently approved treatments
Shares tanked Wednesday on little more than a two-sentence comment from the president-elect.
In recent trading, shares of Five Prime Therapeutics, Inc have crossed above the average analyst 12-month target price of $56.00, changing hands for $57.76/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.